To compare characteristics and outcomes of patients receiving dalbavancin in clinical practice who met DOTS criteria with those enrolled in the DOTS trial.
Key Findings:
31 patients were included in the analysis compared to 200 participants in the DOTS trial.
Patients in the clinical cohort were younger (mean age 44.9 years) than DOTS participants (mean age 56.8 years).
Higher rates of methicillin-resistant S aureus and right-sided endocarditis were observed in the clinical cohort.
Day 70 clinical success was 65% in the clinical cohort versus 80% in DOTS, influenced by higher loss to follow-up in the clinical group.
No deaths or adverse events were reported in the clinical cohort, with high therapy completion rates (94%).
Interpretation:
Limitations:
Retrospective design and small sample size.
Inability to identify all eligible patients and substantial loss to follow-up.
Study period preceded publication of the DOTS trial, reflecting pretrial prescribing patterns.
by Sarah A. Uhm, Bryan T. Alexander, Elizabeth R. Lyden, Nicolas Cortes-Penfield, Harlan R. Sayles, Sara F. Azimi, Mackenzie R. Keintz, Molly M. Miller, Mark E. Rupp, Jasmine R. Marcelin
